TR200003544T2 - Therapeutic combinations for the treatment of musculoskeletal weakness. - Google Patents
Therapeutic combinations for the treatment of musculoskeletal weakness.Info
- Publication number
- TR200003544T2 TR200003544T2 TR2000/03544T TR200003544T TR200003544T2 TR 200003544 T2 TR200003544 T2 TR 200003544T2 TR 2000/03544 T TR2000/03544 T TR 2000/03544T TR 200003544 T TR200003544 T TR 200003544T TR 200003544 T2 TR200003544 T2 TR 200003544T2
- Authority
- TR
- Turkey
- Prior art keywords
- compositions
- treatment
- therapeutic combinations
- oxo
- breakdown
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 230000015556 catabolic process Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 229940047889 isobutyramide Drugs 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000001009 osteoporotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Bu bulus, (-)-cis-6-fenil-5-(4-2-pirolidin-1-il-etoksi)- fenil-5,6,7,8- tetrahidronaftalin-2-ol ve bunun farmasötik açidan kabul gören bir tuzunu ve 2-amino-N-(2-(3a(R)-benzil-2-metil-3-okso-2,3, 3a,4,6,7-heksahidro-pirazolo-[4,3-c]piridin-5-il)-1 (R)-benziloksimetil-2- okso - etil) -izobutiramit veya bunun farmasötik açidan kabul gören bir tuzunu içeren farmasötik kombinasyon kompozisyonlarina, bu kompozisyonlarin kullanim metotlarina ve bu kompozisyonlari ihtiva eden kitlere yöneliktir. Kompozisyonlar; osteoporoz, osteoporotik kirilma, düsük kemik kitlesi, kirilganlik ve düsük kas kitlesi dahil olamak üzere kas-iskelet zayifliginin tedavisinde faydalidir.This invention is (-) - cis-6-phenyl-5- (4-2-pyrrolidin-1-yl-ethoxy) - phenyl-5,6,7,8-tetrahydronaphthalen-2-ol and its pharmaceutically acceptable a salt and 2-amino-N- (2- (3a (R) -benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo- [4,3-c ] is intended for pharmaceutical combination compositions containing pyridin-5-yl) -1 (R) -benzyloxymethyl-2- oxo-ethyl) -isobutyramide or a pharmaceutically acceptable salt thereof, methods of using these compositions, and kits containing these compositions. Compositions; It is useful in the treatment of musculoskeletal weakness, including osteoporosis, osteoporotic breakdown, low bone mass, breakdown, and low muscle mass.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8946998P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200003544T2 true TR200003544T2 (en) | 2001-04-20 |
Family
ID=22217825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2000/03544T TR200003544T2 (en) | 1998-06-16 | 1999-06-16 | Therapeutic combinations for the treatment of musculoskeletal weakness. |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1087764A1 (en) |
| JP (1) | JP2002518326A (en) |
| KR (1) | KR20010052852A (en) |
| CN (1) | CN1301160A (en) |
| AP (1) | AP9901582A0 (en) |
| AR (1) | AR018869A1 (en) |
| AU (1) | AU4054799A (en) |
| BG (1) | BG105041A (en) |
| BR (1) | BR9911324A (en) |
| CA (1) | CA2335134A1 (en) |
| CO (1) | CO5070587A1 (en) |
| EA (1) | EA200001186A1 (en) |
| GT (1) | GT199900087A (en) |
| HN (1) | HN1999000097A (en) |
| HR (1) | HRP20000859A2 (en) |
| HU (1) | HUP0102505A3 (en) |
| ID (1) | ID27599A (en) |
| IL (1) | IL138630A0 (en) |
| IS (1) | IS5691A (en) |
| MA (1) | MA26652A1 (en) |
| NO (1) | NO20006312L (en) |
| OA (1) | OA11505A (en) |
| PA (1) | PA8475901A1 (en) |
| PE (1) | PE20000646A1 (en) |
| PL (1) | PL344981A1 (en) |
| SK (1) | SK18912000A3 (en) |
| TN (1) | TNSN99124A1 (en) |
| TR (1) | TR200003544T2 (en) |
| WO (1) | WO1999065486A1 (en) |
| ZA (1) | ZA993975B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2360103A1 (en) * | 1999-02-08 | 2000-08-17 | Robert Sladek | Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha |
| EP1156120B1 (en) | 2000-05-08 | 2006-11-22 | Pfizer Products Inc. | Enzymatic resolution of selective estrogen receptor modulators |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| CA2420535A1 (en) * | 2000-08-30 | 2002-03-07 | Mary Tanya Am Ende | Sustained release formulations for growth hormone secretagogues |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2006024931A2 (en) * | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| ES2604943T3 (en) | 2007-02-09 | 2017-03-10 | Ocera Therapeutics, Inc. | Ghrelin receptor macrocyclic modulators and procedures for their use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-06-15 PE PE1999000528A patent/PE20000646A1/en not_active Application Discontinuation
- 1999-06-15 ZA ZA9903975A patent/ZA993975B/en unknown
- 1999-06-15 AR ARP990102848A patent/AR018869A1/en not_active Application Discontinuation
- 1999-06-15 AP APAP/P/1999/001582A patent/AP9901582A0/en unknown
- 1999-06-15 PA PA19998475901A patent/PA8475901A1/en unknown
- 1999-06-15 HN HN1999000097A patent/HN1999000097A/en unknown
- 1999-06-16 TR TR2000/03544T patent/TR200003544T2/en unknown
- 1999-06-16 MA MA25628A patent/MA26652A1/en unknown
- 1999-06-16 HU HU0102505A patent/HUP0102505A3/en unknown
- 1999-06-16 ID IDW20002627A patent/ID27599A/en unknown
- 1999-06-16 CO CO99037622A patent/CO5070587A1/en unknown
- 1999-06-16 GT GT199900087A patent/GT199900087A/en unknown
- 1999-06-16 EA EA200001186A patent/EA200001186A1/en unknown
- 1999-06-16 JP JP2000554366A patent/JP2002518326A/en active Pending
- 1999-06-16 CA CA002335134A patent/CA2335134A1/en not_active Abandoned
- 1999-06-16 SK SK1891-2000A patent/SK18912000A3/en unknown
- 1999-06-16 HR HR20000859A patent/HRP20000859A2/en not_active Application Discontinuation
- 1999-06-16 AU AU40547/99A patent/AU4054799A/en not_active Abandoned
- 1999-06-16 BR BR9911324-4A patent/BR9911324A/en not_active Application Discontinuation
- 1999-06-16 PL PL99344981A patent/PL344981A1/en not_active Application Discontinuation
- 1999-06-16 WO PCT/IB1999/001117 patent/WO1999065486A1/en not_active Ceased
- 1999-06-16 EP EP99923802A patent/EP1087764A1/en not_active Withdrawn
- 1999-06-16 KR KR1020007014186A patent/KR20010052852A/en not_active Ceased
- 1999-06-16 CN CN99806237A patent/CN1301160A/en active Pending
- 1999-06-16 TN TNTNSN99124A patent/TNSN99124A1/en unknown
- 1999-06-16 IL IL13863099A patent/IL138630A0/en unknown
-
2000
- 2000-10-20 OA OA1200000290A patent/OA11505A/en unknown
- 2000-10-27 IS IS5691A patent/IS5691A/en unknown
- 2000-12-11 BG BG105041A patent/BG105041A/en unknown
- 2000-12-12 NO NO20006312A patent/NO20006312L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SK18912000A3 (en) | 2001-10-08 |
| AR018869A1 (en) | 2001-12-12 |
| CO5070587A1 (en) | 2001-08-28 |
| BG105041A (en) | 2001-08-31 |
| AU4054799A (en) | 2000-01-05 |
| MA26652A1 (en) | 2004-12-20 |
| GT199900087A (en) | 2000-12-07 |
| TNSN99124A1 (en) | 2005-11-10 |
| PE20000646A1 (en) | 2000-08-05 |
| JP2002518326A (en) | 2002-06-25 |
| WO1999065486A1 (en) | 1999-12-23 |
| AP9901582A0 (en) | 1999-06-30 |
| PA8475901A1 (en) | 2000-05-24 |
| EA200001186A1 (en) | 2001-06-25 |
| KR20010052852A (en) | 2001-06-25 |
| CA2335134A1 (en) | 1999-12-23 |
| IS5691A (en) | 2000-10-27 |
| ID27599A (en) | 2001-04-12 |
| HUP0102505A2 (en) | 2001-11-28 |
| IL138630A0 (en) | 2001-10-31 |
| HRP20000859A2 (en) | 2001-04-30 |
| EP1087764A1 (en) | 2001-04-04 |
| NO20006312D0 (en) | 2000-12-12 |
| NO20006312L (en) | 2000-12-12 |
| HN1999000097A (en) | 1999-11-03 |
| BR9911324A (en) | 2001-04-03 |
| CN1301160A (en) | 2001-06-27 |
| PL344981A1 (en) | 2001-11-19 |
| OA11505A (en) | 2004-05-07 |
| ZA993975B (en) | 2000-12-15 |
| HUP0102505A3 (en) | 2002-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60037836D1 (en) | ThiazoloÄ4,5-diphyrimidine compounds for the treatment of rheumatoid arthritis | |
| LU91710I2 (en) | Pazopanib, optionally in the form of a pharmaceutically acceptable salt or solvate thereof | |
| CY1108874T1 (en) | USE OF IK-KINASE ANALYPES IN PAIN TREATMENT | |
| TR199802273T2 (en) | Fibrotic lezyonlar�n onar�lmas� ve nlenmesi. | |
| IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
| HUP0500173A2 (en) | Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them | |
| MY131911A (en) | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2h-benzopyran or dihydrobenzodioxin) carboxamide derivatives | |
| SI1509232T1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
| GB0223040D0 (en) | Therapeutic compounds | |
| IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
| NO944643D0 (en) | Protein kinase C inhibitors | |
| SV2003000633A (en) | NEW TIADIAZOLS AND OXADIAZOLS AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASA-7 | |
| BR0014381A (en) | Derivatives of 5-beta-sapogenin and pseudosapogenin and their use in the treatment of dementia | |
| DK1546127T3 (en) | New pyrimidinamide derivatives and their use | |
| ATE332903T1 (en) | CONDENSED PYRIDOINDOLE DERIVATIVES | |
| IL94278A0 (en) | 2-saccharine derivatives,their preparation and pharmaceutical compositions containing them | |
| TR200003544T2 (en) | Therapeutic combinations for the treatment of musculoskeletal weakness. | |
| BRPI0410663A (en) | hydroxyamidine and hydroxyguuanidine compounds as urokinase inhibitors | |
| UA66872C2 (en) | Pharmaceutical compositions comprising olanzapine or olanzapine pamoate or solvates and method for treating psychotic disorders | |
| NZ330944A (en) | Peptide derivatives | |
| ES2088128T3 (en) | ACAT INHIBITOR AMINOSULFONILUREAS. | |
| BR9813719A (en) | Therapeutic agents | |
| DK0996435T3 (en) | Amino acid derivatives useful for the treatment of stroke | |
| AP9901581A0 (en) | Therapeutic combinations for musculoskeletal frailty. | |
| BR0111102A (en) | Use of (+) - alpha (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4pipyridinomethanol or its prodrug in the treatment of symptoms of dementia and dopamine-induced psychosis |